Table 1.
Characteristics of studies included for meta-analysis. Cut-off value: median expression
| First author | Year | Duration (months) | Histology | Stage | Patient number | Quality score | Detection | Platform |
|---|---|---|---|---|---|---|---|---|
| Okayama H [41] | 2011 | 120 | ADC | I–II | 226 | 9 | Microarray | Affymetrix Hgu133plus2.0 |
| Hou J [42] | 2010 | 130 | NSCLC | NR | 91 | 9 | Microarray | AffymetrixHgu133plus2.0 |
| Tang H [43] | 2013 | 120 | NSCLC | I–III | 176 | 9 | Microarray | IlluminaHumanWG-6v3.0 |
| Zhu CQ [44] | 2010 | 108 | NSCLC | IB–II | 133 | 9 | Microarray | AffymetrixHgu133a |
| Raponi M [45] | 2006 | 144 | SQC | I–III | 129 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Bild AH [46] | 2006 | 88 | NSCLC | NR | 111 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Rousseaux S [47] | 2013 | 256 | NSCLC | I–IV | 293 | 9 | Microarray | AffymetrixHgu133plus2.0 |
| Tomida S [48] | 2009 | 109.8 | ADC | I–III | 117 | 9 | Microarray | AgilentWholeHumanGenomeMicroarray 4x44K G4112F |
| Botling J [49] | 2013 | 120 | NSCLC | I–IV | 196 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Shedden K [50] | 2008 | 204 | ADC | I–IV | 333 | 9 | Microarray | AffymetrixHgu133a |
| Beer DG [51] | 2002 | 110.6 | ADC | I–III | 86 | 8 | Microarray | AffymetrixHumanFullLength HuGeneFL |
| Landi MT [52] | 2008 | NR | ADC | I–IV | 74 | 9 | Microarray | AffymetrixHgu133a |
| Lu T [53] | 2010 | NR | ADC | I–IV | 60 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Lee ES [54] | 2008 | 120 | NSCLC | I–III | 138 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Kuner R [55] | 2009 | NR | NSCLC | NR | 58 | 8 | Microarray | AffymetrixHgu133plus2.0 |
| Selamat SA [56] | 2012 | NR | ADC | I–III | 58 | 8 | Microarray | IlluminaHumanWG-6v3.0 expression |
| Meyerson M [57] | 2015 | NR | SQC | I–IV | 135 | 8 | Microarray | AffymetrixHgu133a |
NR not reporting, ADC lung adenocarcinoma, SQC lung squamous cell carcinoma